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Abstract: Several in vivo and in vitro studies have demonstrated the involvement of infectious 
agents in the development of atherosclerosis. However, the mechanisms by which micro-organisms 
induce and/or aggravate atherosclerosis, are so far unclear. Accumulation of cholesterol esters and 
lipid laden cell formation are hallmark of the atherogenesis, however, the possible relationship   
between cholesterol esterification and the signal-transducing component of LPS recognition 
complex inducing cytokine secretion has not been yet investigated. 
In the present study, we investigated the effect of mevinolin, the ACAT inhibitor, Sandoz 58035, 
and plasma from statin-treated hypercholesterolemic patients on cholesterol metabolism and 
cytokine expression in LPS activated P388D1 macrophages. In P388D1 macrophages cholesterol 
synthesis and uptake, as well as cholesterol ester synthesis, were unchanged following LPS-
activation. When cells were grown in presence of serum from patients under statin therapy, 
cholesterol esterification was lower compared to cells grown with plasma from healthy subjects, 
independently from the type of statin used. This effect was accompanied by inhibition of IL-1β 
expression in LPS activated cells. The ACAT inhibitor, Sandoz 58035, which completely blocked 
cholesterol esterification in normal and LPS-activated macrophages, prevented IL-1β and IL-6 over-
expression in LPS activated cells. Although preliminary, these data point to a possible relationship 
between cholesterol esterification and cytokine production in macrophages, prospecting new 
possible mechanisms by which microbial or inflammatory agents may induce and/or accelerate the 
atherosclerotic process.  
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INTRODUCTION 
 
Inflammation as well as infectious diseases are 
considered
[1-3] the new emerging risk factors for 
atherosclerosis. Inflammation is instrumental in 
developing atherosclerotic lesions and plays a crucial 
role in the plaque destabilisation, thus converting 
chronic atherosclerosis into an acute thrombo-embolic 
disorder.
[4,5] Humoral factors involved in 
destabilisation include cytokines, cyclooxygenases, 
matrix metalloproteinases, and tissue factor. Markers 
of inflammation and infection also significantly 
influence the occurrence of cerebrovascular events in 
patients with baseline asymptomatic carotid lesions
[6].  
Several experimental and clinical observations have 
documented the involvement of infectious agents in 
enhancing formation of atherosclerosis lesions. The 
proposed mechanisms include: i) oxidation of Low 
Density Protein (LDL), ii) altered monocyte adhesion 
iii) increased production of inflammatory cytokines. 
However, no definite mechanism has been so far 
recognized to fully explain experimental and clinical 
observations.
[7,8] 
Circulating lipopolysaccharide (LPS) is not 
confined to sepsis but also occurs in healthy subjects 
and it is often associated with accelerated progression 
of  atherosclerosis,
[9] suggesting that a blunted 
inflammatory response due to ineffective removal of 
infectious agents might be a persistent insult for the Am. J. Infect. Dis., 3 (3): 151-158, 2007 
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arterial wall. Furthermore, a continuous eliciting of 
the innate immune system may worsen inflammation 
in the atherosclerotic plaque leading to its swollen. 
The signal-transducing component of the LPS 
recognition complex induces cytokine secretion,
[10,11] 
however, although cholesterol esters and lipid laden 
cell formation are hallmark of the atherogenesis, the 
possible relationship between cholesterol esterification 
and inflammatory response to LPS has not been yet 
investigated. 
In the present study we studied, in LPS activated 
P388D1 macrophages, the effect of mevinolin, (an 
inhibitor of hydroxy-methyl CoA-reductase [HMG-
CoA-r]), of Sandoz 58035 (an inhibitor of acyl-
coenzyme-A cholesterol-acyl-transferase  [ACAT]), 
and of sera from Statin-Treated Hypercholesterolemic 
Patients (STHP) on cholesterol metabolism and 
cytokine expression. We used inhibitors of HMGCoA-
reductase given their effect in inhibiting both: i) 
cholesterol metabolism
[12] and ii) inflammatory 
molecule production in macrophages.
[13] 
 
MATERIALS AND METHODS 
 
[
14C]-acetic acid (specific activity 2.0 GBq/mmol) 
and [
14C]oleic acid (specific activity 1.9 GBq/mmol) 
were purchased by NEN (PerkinElmer Inc., Milano, 
Italy), RPMI 1640, Foetal Calf Serum (FCS), were 
purchased from GIBCO Laboratoires (Gaithersburg, 
MD, USA). Reagents for ELISA were obtained from 
Biosource (Prodotti Gianni, Milano, ITALY), 
Acetilated–LDL (ac-LDL) were purchased from Alma 
Export (Firenze, Italy). Mevinolin (Sigma, Milano, 
Italy) and Sandoz 58-035 was kindly donated by 
Novartis (East Hanover, N.J., USA). All other 
reagents were purchased from Sigma (Milano, 
ITALY) unless stated. 
 
Cell culture:  This study used the mouse macrophage-
like cell line P388D1, obtained from American Type 
Culture Collection (Istituto Zooprofilattico, Brescia, 
Italy). Cells were grown at 37°C, in a 5% CO2 
atmosphere to a density of 10
6 cells/ml. Growth 
medium was RPMI 1640 supplemented with 10% FCS, 
50 U/ml penicillin, and 50 U/ml streptomycin. For 
some experimental purposes medium was 
supplemented with 10% sera from STHP (atorvastatin 
or sinvastatin), as control, sera from healthy volunteers 
were used.  
For each experiment, the appropriate 
concentration of drugs were used: 100 ng/ml LPS, 
Sandoz 58035 4 µM solubilised in dimethyl sulfoxide 
(Me2SO, concentration did not exceed 0.2%) and 
mevinolin 0.5 µM (sodium salt of the open acid form) 
were added to cells.  
Cell number was determined with a Coulter Counter 
and corrected for viability, as determined by trypan 
blue dye exclusion. 
 
Preparation of human sera: Male 
hypercholesterolemic patients (n=6) were enrolled in 
this study. They did not suffer of hypertension, 
diabetes and obesity and, beside statins, were not 
under any therapy. Three patients were treated with 
sinvastatin (40 mg/die) and the other three with 
atorvastatin (40 mg/die). Such statins were chosen 
since differ for chemical properties and half life.
[12] 
The blood was drown early in the morning, before 
drug administration. After centrifugation at 800 rpm, 
red cells were removed and the supernatant 
centrifuged at 9000 rpm to remove platelets. Thus sera 
were incubated at 56°C, for 30 min, centrifuged and 
complement removed. Afterward sera were filtered in 
0.2 µm filter and frozen at -80 °C until use. Sera 
obtained from healthy donors (n=5) were processed in 
the same way and used as control.  
 
Determination of cholesterol synthesis: To 
determine the rate of cholesterol synthesis 10
6/ml cells 
were incubated for 3 hrs with 185 kBq/ml of sodium 
[
14C]-acetate. After incubation cells were separated by 
centrifugation and collected. Cell lipids were extracted 
with cold acetone and neutral lipids separated by thin 
layer chromatography (TLC) Kiesegel plates using a 
solvent system containing eptane/isopropylether/ 
formic acid (60:40:2 v/v/v). Free cholesterol and 
cholesterol ester bands were identified by comparison 
with standards running simultaneously with samples 
and visualised using iodine vapour.
[14] For counting, 
the bands were excised and added directly to counting 
vials containing 10 ml of Ultima Gold. All incubations 
were carried out in triplicate and the results for 
individual experiments are given as mean values, 
variation between triplicates was less than 10%. All 
data are expressed as the rate of [
14C]-acetate 
incorporation into cholesterol per µg protein. 
 
Determination of cholesterol esterification: Cells 
were incubated for 4 hours in medium containing 
[
14C]-oleate bound to bovine serum albumin (BSA). 
To prepare the oleate-BSA complex, 3.7 MBq of 
[
14C]-oleic acid in ethanol (specific activity 2.035 
GBq/mmol) was mixed with 1.4 mg KOH and the 
ethanol evaporated. PBS (1.5 ml) without Ca
2+ and 
Mg
+ containing 4.24 mg BSA (fatty acid-free) was Am. J. Infect. Dis., 3 (3): 151-158, 2007 
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added and the mixture shaken vigorously. This 
solution was added to each well at a final 
concentration of 74 KBq/ml. After incubation cells 
were washed with ice-cold PBS and lipids extracted 
with acetone. Neutral lipids were separated by TLC as 
previously described
[14] and incorporation of [
14C] 
oleate into cholesterol esters was measured. An 
aliquot of cell lysate was processed for protein 
content
[15]. 
 
Cellular protein isolation and Western blotting 
analysis:  The cells were lysed in a PBS buffer 
containing 10% SDS, 50 µg TRIS, 1 µM EDTA, pH 
7.5, 50 µM DTT and a protease inhibitor cocktail, at 
37°C and homogenised by a syringe fitted with an 18-
gauge needle. Protein content of each sample was 
determined by Bradford protein assay
[16] (Bio-Rad 
Laboratories, Hemel Hempstead, UK). Protein 
samples (30µg/lane) were separated by electrophoresis 
(12% SDS acrylamide gel) and transferred to a PVDF 
membrane (Invitrogen, Milano, Italy) by standard 
electro-blotting procedure. The blots were pre-treated 
with a solution containing 5% non fat dried milk in 
TBST at room temperature (50=µM TRIS-HCl, pH 
7.6, 0.15 M NaCl, and 0.05% Tween-20) for at least 
one hour before the addition of the primary antibodies 
(dilution range varying from 1:1000 to 1:3000) for 
mouse interleukin-1β (IL-1β) and interleukin-6 (IL-6) 
(Santa Cruz Biotechnology, Santa Cruz, CA). After an 
overnight incubation the primary antibodies were 
removed and appropriate horseradish peroxidase-
conjugated secondary antibodies (Santa Cruz 
Biotechnology, Santa Cruz, CA) were added in a 
dilution range of 1:2500 to 1:5000 for at least 1h at 
room temperature. Proteins were detected by enhanced 
chemiluminescence and by exposure to X-ray film, 
(Amersham Pharmacia Biotech, Milano, Italy) for 
various times. Quantification of the protein bands was 
then accomplished by densitometry (Scion Imagine, 
NIH).  
 
Statistical analysis: Data analyses were performed by 
one- or two-way analysis of variance (ANOVA) for 
repeated measures followed by Newman-Keuls or 
Dunnett tests when appropriate. Differences were 
considered significant if P<0.05. 
 
RESULTS 
 
Sera from STHP inhibit cholesterol esterification 
in P388D1 macrophages: As shown in fig. 1, except 
for one case, cholesterol esterification in cells cultured 
in presence of sera from STHP was significantly lower 
compared to cells growing in presence of sera from 
healthy volunteers. The extent of inhibition 
significantly differed between samples ranging from 
25 to 62% vs control (P<0.05) independently from the 
statin administered. 
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Fig 1:   P388D1  cells  (2x10
5/ml) were incubated for 48 
hours in RPMI 1640 medium containing human 
plasma obtained from healthy volunteers or STHP 
(sinvastatin and atorvastatin). Four hours before 
harvesting [
14C]-oleate was added to the culture 
medium. At the end of incubation cells were 
harvested and processed as described in Materials 
and Methods. Each value represents the mean ± 
S.E.M. of triplicate samples. *P<0.05 vs control 
(Dunnett’s test). 
 
 
Sera from STHP inhibit cholesterol esterification 
in LPS-activated P388D1 macrophages: As shown 
in fig. 2, cholesterol esterification did not change in 
LPS-stimulated P388D1 macrophages growing in sera 
from healthy volunteers. On the contrary, LPS-
activated cells cultured in presence of sera from STHP 
showed a significant reduction of cholesterol 
esterification, the effect being independent from the 
type of statin administered (P<0.001). Am. J. Infect. Dis., 3 (3): 151-158, 2007 
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Fig 2:  P388D1 cells (2x10
5/ml) were incubated for 48 hrs 
in RPMI 1640 medium containing human sera 
obtained from healthy volunteers or STHP 
(sinvastatin and atorvastatin) and stimulated with 
LPS (100 ng/ml) or vehicle (-LPS). Four hours 
before harvesting [
14C]-oleate was added to the 
culture medium. At the end of incubation cells 
were harvested and processed as described in 
Materials and Methods. Each value represents the 
mean ± S.E.M. of triplicate samples of a 
representative experiment. *P<0.001 vs control 
group (Dunnett’s test). 
 
 
Sera from STHP restrains the increase of IL-1β 
exspression in LPS-activated P388D1 
macrophages: As shown in fig. 3 the incubation of 
LPS-activated macrophages with sera from STHP 
prevents the increase of IL-1β expression. Panel A 
illustrates the autoradiography of IL-1β in LPS-
activated P388D1 cells and is representative of three 
different experiments. Fig. 3B shows the quantitative 
densitometric determination of the bands after 
normalisation with β-actin. The extent of inhibition of 
cytokine expression in LPS-activated macrophages 
incubated with sera from STHP varied from 40% to 
70%. 
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Fig 3:  P388D1  cells  (2x10
5/ml) were incubated for 48 
hours in RPMI 1640 medium containing human 
sera obtained from healthy volunteers or patients 
STHP (sinvastatin and atorvastatin) therapy and 
stimulated with LPS (100 ng/ml). For protein 
extraction and western blotting analysis see 
Materials and Methods (Panel A: autoradiography 
representative of three experiments). 
Quantification of the immunoblots were 
performed by Scion Imagine (Panel B). Each value 
represents the mean ± S.E.M. of triplicate sample. 
*P<0.001 vs control (Dunnett’s test).  
 
 
 
Mevinolin but not the ACAT inhibitor Sandoz 58035 
inhibits cell proliferation and cholesterol synthesis: 
Fig. 4 shows that mevinolin significantly (P<0.001)  
reduced cell proliferation (panel A) in a dose-dependent 
manner. Concentrations of mevinolin higher than 0.5 
µM were cytotoxic, thus this dose was utilized for the 
successive experiments. On the contrary, the ACAT 
inhibitor, Sandoz 58035 does not affect cell 
proliferation even at incubation doses up to 200 µM. It 
is worthy to  note that this compound completely 
inhibits cholesterol esterification at 4 µM dose (data not 
shown). As shown in the Fig. 4B mevinolin was also 
able to significantly inhibit cholesterol synthesis 
(P<0.001), while Sandoz 58035 was ineffective.  
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Fig 4:  P388D1 cells (2x10
5/ml) were incubated for 72 hrs 
in RPMI 1640 medium supplemented with 10% 
FCS and treated with Sandoz 58035 (4 µM) or 
Mevinolin (0.5, 1 and 2 µM) (Panel A). Cells were 
harvested at the indicated times and cell number 
evaluated. Panel B. Cells were cultured as Panel A 
and treated with Sandoz 58035 (4 µM) and 
Mevinolin (0.5 µM). Three hours before 
harvesting macrophages were incubated for 3 hrs 
with 185 kBq/ml of sodium [
14C]-acetate. At the 
end of incubation they were harvested and 
processed as described in Materials and Methods. 
All incubations were carried out in triplicate and 
the results expressed as mean ± S.E.M. *P<0.001 
vs control (Newman-Keuls test). 
 
LPS potentiates the rate of cholesterol ester 
synthesis induced by ac-LDL: As shown in fig. 5, 
although LPS alone does not influence cholesterol  
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Fig 5:  P388D1 cells (2x10
5/ml) were incubated for 48 hrs 
in RPMI 1640 medium 10% FCS. The cells were 
divided into four groups: vehicle, LPS (100 
ng/ml), ac-LDL (100 µg/ml), LPS + ac-LDL. Four 
hours before harvesting, [
14C]-oleate was added to 
the culture medium. At the end of incubation cells 
were harvested and processed as described in 
Materials and Methods. Each value represents the 
mean ± S.E.M. of triplicate experiments. *P<0.001 
vs vehicle; **P<0.05 vs ac-LDL groups (Newman-
Keuls test).  
 
 
 
ester synthesis in P388D1 macrophages, it potentiates 
the increase of cholesterol esterification resulting from 
the addition of ac-LDL (P<0.05). 
 
Sandoz 58035 and Mevinolin inhibit cholesterol 
esterification in LPS-activated cells: Sandoz 58035 
completely inhibited cholesterol esterification (98% 
inhibition, P<0.001) in activate and LPS-activated 
cells. A similar effect, even if at minor extent, was 
observed in Mevinolin treated cells (P<0.001)(Fig. 6). 
 
Sandoz 58035 and Mevinolin prevent the induction 
of IL-1β and IL-6 expression in LPS activated 
macrophages: LPS induced expression of  IL-1β and 
IL-6 in P388D1 cells, this effect being partially 
prevented by Sandoz 58035 or Mevinolin 
administration (P<0.001) (Fig. 7A and B).  
 Am. J. Infect. Dis., 3 (3): 151-158, 2007 
 
  156
0
400
800
1200
*
 -        -        +               -           58035
 -         -            -              +           Mevinolin
  -       +        +      +           LPS
*
[
1
4
C
]
O
l
e
a
t
e
 
i
n
c
o
r
p
o
r
a
t
e
d
 
i
n
 
E
C
D
P
M
/
µ
g
 
o
f
 
p
r
o
t
e
i
n
 
Fig. 6:  P388D1 were cultured at 2x105/ml and incubated 
for 48 hrs with vehicle, LPS (100 ng/ml), LPS(100 
ng/ml) + Sandoz 58035 (4µM), LPS (100 ng/ml) + 
Mevinolin(0,5 µM). Four hours before the end of 
incubations [14C]-oleate was added to the culture 
medium. [
14C]-oleate incorporation into esterified 
cholesterol was determined as described in 
Materials and Methods. Each value represents the 
mean ± S.E.M. of triplicate samples. *P<0.001 and 
vs control and LPS (Dunnett’s test). 
 
DISCUSSION 
 
Macrophages are the major players of innate 
immunity not only protecting against microbial 
infections but also against metabolic antigens, such as 
modified LDL, recognised as foreign pathogens. They, 
in fact, possess a large number of receptors for 
microbial pathogens and numerous tools to destroy 
them following phagocytosis. Recently it has been 
demonstrated that  the binding of microbial LPS with 
the Toll like receptors (TLR4), a new family of 
recognition receptors, activates NF-kappa B, a 
transcription factor responsible for the synthesis of 
numerous molecules, including cytokines
[11]. Modified 
LDL (oxidised, glycated etc.), considered to have an 
important part in the atherogenetic process, are also 
recognised by specific macrophage receptors namely, 
SRA and SRB.
[17-19] 
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Fig.  7:  P388D1 were cultured as in Fig. 6. For protein 
extraction and western blotting analysis see 
Materials and Methods (Panel A: autoradiography 
representative of one experiment). Quantification 
of the immunoblots were performed by Scion 
Imagine (Panel B). Each value represents the mean 
± S.E.M. of triplicate samples. *P<0.001 vs 
control; **P<0.001 vs LPS (Dunnett’s test).  
 
 
However, differently from microbial agents, they 
are not completely degraded following phagocytosis, 
but hydrolytically processed in lysosomes to generate 
free cholesterol (FC) and free fatty acids. Since, if in 
excess, FC may be toxic, it is re-esterified by the ER-
resident enzyme ACAT and in this form  stored in 
droplets in the cytoplasm.
[21] Persistence of high levels 
of modified LDL coupled with a defective reverse 
cholesterol transport could thus engulf macrophages 
that assume the peculiar foam cell shape. Thus, it 
seems that mechanisms developed by cells to remove 
metabolic and microbial pathogens initially are similar 
(i.e receptor pathways) then they diverge to produce 
cholesterol esters the former and inflammatoryAm. J. Infect. Dis., 3 (3): 151-158, 2007 
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molecules the latter. In the present study, LPS 
activation did not change cholesterol synthesis, as well 
as cholesterol ester synthesis in P388D1 cells. 
However, cholesterol ester synthesis was remarkably 
induced only if LPS was combined with ac-LDL. 
These findings raised the question as to whether in 
humans, infections should increase cholesterol 
esterification, leading to foam cell formation, 
independently from the presence of metabolic risk 
factors. 
Under our experimental conditions, cells growing 
in presence of sera from statin-treated patients, 
esterify cholesterol at lower extent than those growing 
in presence of sera from healthy subjects. On the other 
hand, STHP was also able to inhibit IL-1β production 
in LPS-activated cells. This is not a surprise since it 
has been widely demonstrated that statins inhibit LDL 
endocytosis and exert an inhibitory effect on Rho-
mediated inflammatory pathways 
[13].  
In a attempt to establish whether a direct link 
exists between cholesterol esterification and cytokine 
production, we next investigated the effect of the 
ACAT inhibition, on cholesterol esterification and 
cytokine production in LPS activated P388D1 cells. 
Interestingly, the almost complete inhibition of 
cholesterol esterification exerted by Sandoz 58035 
was accompanied by a remarkable reduction of 
cytokine IL-1β and IL-6 production in LPS induced 
macrophages. The fact that, under our experimental 
conditions, 58035, differently  to statins, did not 
influence other factors possibly involved in cytokine 
production (i.e. cell proliferation and cholesterol 
synthesis) strongly support the hypothesis that 
cholesterol esterification and cytokine production in 
macrophages might be in someway related. 
However, it remains to explain recent evaluations 
of ACAT inhibitors indicating that pharmacological 
inhibition of macrophage ACAT may not reduce, but 
actually aggravate, foam cell formation and 
progression It has been suggested that the block of 
cholesterol esterification could increase free 
cholesterol into the plaque causing its conversion to an 
unstable form prone to rupture.
[21-24]. 
However,  in vitro studies demonstrated that 
ACAT inhibitors induces cytokine production only in 
cholesterol-loaded mouse macrophages
[25]. 
Appropriately, our results showed that ACAT 
inhibition prevents cytokine production following LPS 
in a non cholesterol-loading condition.  
In summary, although preliminary, our data point 
to a possible relationship between cholesterol 
esterification and cytokine production in 
macrophages, prospecting new possible mechanisms 
by which microbial or inflammatory agents may 
induce and/or accelerate the atherosclerotic process. 
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